Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis

Stem Cells

Volumn 26, Issue 8, 2008, Pages 1920-1930

  Bogani, Costanza ^a,b,c   Ponziani, Vanessa ^a,b,c   Guglielmelli, Paola ^a,b,c   Desterke, Cristophe ^d   Rosti, Vittorio ^e   Bosi, Alberto ^a,b,c   Le Bousse Kerdilès, Marie Caroline ^d   Barosi, Giovanni ^e   Vannucchi, Alessandro M ^a,b,c,f  

^a UNIVERSITY OF FLORENCE   (Italy)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c MOUNT SINAI HOSPITAL   (United States)

^d INSERM   (France)

^e C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

Author keywords

CD34+ cell; CXCR4; Epigenetic; Methylation; Myelofibrosis

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; MESSENGER RNA;

ANTIGEN EXPRESSION; ARTICLE; CD34 SELECTION; CELL LINE; CELL MIGRATION; CELL STRAIN HEL; CELL STRAIN HL 60; CELL STRAIN K 562; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; EPIGENETICS; HUMAN; HUMAN CELL; IMMUNITY; INCUBATION TIME; MOLECULAR MECHANICS; MYELOID METAPLASIA; POLYMERASE CHAIN REACTION; PROTEIN METHYLATION;

ANTIGENS, CD34; CELL LINE, TUMOR; CHEMOKINE CXCL12; CPG ISLANDS; DNA METHYLATION; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HL-60 CELLS; HUMANS; K562 CELLS; MUTATION; POLYMERASE CHAIN REACTION; PRIMARY MYELOFIBROSIS; RECEPTORS, CXCR4; RNA, MESSENGER;

EID: 55049114480     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2008-0377     Document Type: Article

References (79)

1. Lataillade JJ, Clay D, Bourin P et al. Stromal cell-derived factor 1 regulates primitive hematopoiesis by suppressing apoptosis and by promoting G(0)/G(1) transition in CD34(+) cells: Evidence for an autocrine/paracrine mechanism. Blood 2002;99:1117-1129.
2. Zou YR, Kottmann AH, Kuroda M et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998;393:595-599.
3. Tachibana K, Hirota S, Iizasa H et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998;393:591-594.
4. Nagasawa T, Hirota S, Tachibana K et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996;382:635-638.
5. Peled A, Petit I, Kollet O et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science 1999;283:845-848.
6. Müller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-56.
7. Sun YX, Wang J, Shelburne CE et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem 2003;89:462-473.
8. Voermans C, van Heese WP, de Jong I et al. Migratory behavior of leukemic cells from acute myeloid leukemia patients. Leukemia 2002;16:650-657.
9. Tavor S, Petit I, Porozov S et al. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 2004;64:2817-2824.
10. Peled A, Kollet O, Ponomaryov T et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: Role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 2000;95:3289-3296.
11. Hattori K, Heissig B, Tashiro K et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 2001;97:3354-3360.
12. Petit I, Szyper-Kravitz M, Nagler A et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nature Immunology 2002;3:687-694.
13. Lévesque JP, Hendy J, Takamatsu Y et al. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003;111:187-196.
14. Voermans C, Kooi ML, Rodenhuis S et al. In vitro migratory capacity of CD34+ cells is related to hematopoietic recovery after autologous stem cell transplantation. Blood 2001;97:799-804.
15. Dlubek D, Drabczak-Skrzypek D, Lange A. Low CXCR4 membrane expression on CD34(+) cells characterizes cells mobilized to blood. Bone Marrow Transplant 2006;37:19-23.
16. Shen H, Cheng T, Olszak I et al. CXCR-4 desensitization is associated with tissue localization of hemopoietic progenitor cells. J Immunol 2001;166:5027-5033.
17. Kim HK, De La Luz Sierra M, Williams CK et al. G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood 2006;108:812-820.
18. De La Luz Sierra M, Gasperini P, McCormick PJ et al. Transcription factor Gfi-1 induced by G-CSF is a negative regulator of CXCR4 in myeloid cells. Blood 2007;110:2276-2285.
19. Brühl H, Cohen CD, Linder S et al. Post-translational and cell type-specific regulation of CXCR4 expression by cytokines. Eur J Immunol 2003;33:3028-3037.
20. Wynn RF, Hart CA, Corradi-Perini C et al. A small proportion of mesenchymal stem cells strongly expresses functionally active CXCR4 receptor capable of promoting migration to bone marrow. Blood 2004;104:2643-2645.
21. Busillo JM, Benovic JL. Regulation of CXCR4 signaling. Biochim Biophys Acta 2007;1768:952-963.
22. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005;23:8520-8530.
23. Barosi G, Viarengo G, Pecci A et al. Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 2001;98:3249-3255.
24. Massa M, Rosti V, Ramajoli I et al. Circulating CD34+, CD133+, and vascular endothelial growth factor receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia. J Clin Oncol 2005;23:5688-5695.
25. Yoder MC, Mead LE, Prater D et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007;109:1801-1809.
26. Xu M, Bruno E, Chao J et al. Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. Blood 2005;105:4508-4515.
27. Xu M, Bruno E, Chao J et al. The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. Blood 2005;105:1699-1705.
28. Rosti V, Massa M, Vannucchi AM et al. The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis 2007;38:280-286.
29. Guglielmelli P, Zini R, Bogani C et al. Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). STEM CELLS 2007;25:165-173.
30. Barosi G, Ambrosetti A, Finelli C et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol 1999;104:730-737.
31. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302.
32. Vannucchi AM, Pancrazzi A, Bogani C et al. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia 2006;20:1055-1060.
33. Guglielmelli P, Pancrazzi A, Bergamaschi G et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol 2007;137:244-247.
34. Dupriez B, Morel P, Demory JL et al. Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system. Blood 1996;88:1013-1018.
35. Keeney M, Chin-Yee I, Weir K et al. Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering. Cytometry 1998;34:61-70.
36. Vannucchi AM, Pancrazzi A, Guglielmelli P et al. Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. Am J Pathol 2005;167:849-858.
37. van der Velden VH, Hochhaus A, Cazzaniga G et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: Principles, approaches, and laboratory aspects. Leukemia 2003;17:1013-1034.
38. Migliaccio AR, Martelli F, Verrucci M et al. Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the GATA1 low mouse model of the disease. Exp Hematol 2008;36:158-171.
39. Martyré MC, Romquin N, Le Bousse-Kerdiles MC et al. Transforming growth factor-beta and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol 1994;88:9-16.
40. Chagraoui H, Komura E, Tulliez M et al. Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood 2002;100:3495-3503.
41. Vannucchi AM, Bianchi L, Paoletti F et al. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis. Blood 2005;105:3493-3501.
42. Nagase H, Miyamasu M, Yamaguchi M et al. Cytokine-mediated regulation of CXCR4 expression in human neutrophils. J Leukoc Biol 2002;71:711-717.
43. Shirazi Y, Pitha PM. Interferon downregulates CXCR4 (fusin) gene expression in peripheral blood mononuclear cells. J Hum Virol 1998;1:69-76.
44. Sato N, Matsubayashi H, Fukushima N et al. The chemokine receptor CXCR4 is regulated by DNA methylation in pancreatic cancer. Cancer Biol Ther 2005;4:70-76.
45. Mori T, Kim J, Yamano T et al. Epigenetic up-regulation of C-C chemokine receptor 7 and C-X-C chemokine receptor 4 expression in melanoma cells. Cancer Res 2005;65:1800-1807.
46. Kubarek L, Jagodzinski PP. Epigenetic up-regulation of CXCR4 and CXCL12 expression by 17 beta-estradiol and tamoxifen is associated with formation of DNA methyltransferase 3B4 splice variant in Ishikawa endometrial adenocarcinoma cells. FEBS Lett 2007;581:1441-1448.
47. Levine RL, Pardanani A, Tefferi A et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007;7:673-683.
48. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006;355:2452-2466.
49. Levine RL, Wadleigh M, Cools J et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397.
50. Campbell PJ, Griesshammer M, Dohner K et al. V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 2006;107:2098-2100.
51. Barosi G, Bergamaschi G, Marchetti M et al. JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood 2007;110:4030-4036.
52. Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790.
53. Baxter EJ, Scott LM, Campbell PJ et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061.
54. Pardanani AD, Levine RL, Lasho T et al. MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients. Blood 2006;108:3472-3476.
55. Pikman Y, Lee BH, Mercher T et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270.
56. Skoda R. The genetic basis of myeloproliferative disorders. Hematology Am Soc Hematol Educ Program 2007;2007:1-10.
57. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: Epigenetics joins genetics. Trends Genet 2000;16:168-174.
58. Guglielmelli P, Tozzi L, Pancrazzi A et al. MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Exp Hematol 2007;35:1708-1718.
59. Shilatifard A. Chromatin modifications by methylation and ubiquitination: Implications in the regulation of gene expression. Annu Rev Biochem 2006;75:243-269.
60. Eckhardt F, Lewin J, Cortese R et al. DNA methylation profiling of human chromosomes 6, 20 and 22. Nat Genet 2006;38:1378-1385.
61. Cameron EE, Bachman KE, Myohanen S et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21:103-107.
62. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. New Engl J Med 2003;349:2042-2054.
63. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nature Reviews 2002;3:415-428.
64. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006;6:38-51.
65. Costello JF, Fruhwald MC, Smiraglia DJ et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000;24:132-138.
66. Rakyan VK, Hildmann T, Novik KL et al. DNA methylation profiling of the human major histocompatibility complex: A pilot study for the human epigenome project. PLoS Biology 2004;2:e405.
67. Kumagai T, Tefferi A, Jones L et al. Methylation analysis of the cell cycle control genes in myelofibrosis with myeloid metaplasia. Leuk Res 2005;29:511-515.
68. Wang JC, Chen W, Nallusamy S et al. Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation. Br J Haematol 2002;116:582-586.
69. Hemavathy KC, Chang TH, Zhang H et al. Reduced expression of TGF beta1RII in agnogenic myeloid metaplasia is not due to mutation or methylation. Leuk Res 2006;30:47-53.
70. Li J, Bench AJ, Huntly BJ et al. Mutation and methylation analysis of the transforming growth factor beta receptor II gene in polycythaemia vera. Br J Haematol 2001;115:872-880.
71. Jones LC, Tefferi A, Idos GE et al. RARbeta2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia. Oncogene 2004;23:7846-7853.
72. Jost E, do ON, Dahl E et al. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia 2007;21:505-510.
73. Capello D, Deambrogi C, Rossi D et al. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. Br J Haematol 2008;141:504-511.
74. Shi J, Zhao Y, Ishii T et al. Effects of chromatin-modifying agents on CD34+ cells from patients with idiopathic myelofibrosis. Cancer Res 2007;67:6417-6424.
75. Geay JF, Buet D, Zhang Y et al. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. Cancer Res 2005;65:2676-2683.
76. Wang JF, Liu ZY, Groopman JE. The alpha-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion. Blood 1998;92:756-764.
77. Majka M, Janowska-Wieczorek A, Ratajczak J et al. Stromal-derived factor 1 and thrombopoietin regulate distinct aspects of human megakaryopoiesis. Blood 2000;96:4142-4151.
78. Hodohara K, Fujii N, Yamamoto N et al. Stromal cell-derived factor-1 (SDF-1) acts together with thrombopoietin to enhance the development of megakaryocytic progenitor cells (CFU-MK). Blood 2000;95:769-775.
79. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005;115:3339-3347.